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18. BONE DISEASE
1. INTRODUCTION
jj CF patients are at increased risk for bone disease compared to age-matched controls. 
jj The prevalence of osteoporosis and osteopenia in CF is difficult to establish (mostly 
due to differences in the definition of osteoporosis/osteopenia in different age groups), 
however, it increases with age, lung disease severity, low body mass index (BMI) and 
malnutrition.
jj Prevention, timely identification and treatment of bone disease are important aspects of 
CF care.
2. PATHOGENESIS OF BONE DISEASE IN CF
jj The main risk factors for low bone mineral density (BMD) in CF are summarized in Table 1. 
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Table 1:  Main Risk factors for low bone mineral density (BMD) in CF  
(adapted from1)
Poor nutritional status, low BMI
Pancreatic insufficiency and malabsorption
Delayed puberty, hypogonadism 
Severity of lung disease (lung infection, chronic inflammation, respiratory failure)
Male gender
Corticosteroids and other immunosuppressive therapies (especially in transplanted patients*)
Physical inactivity
*Severe, symptomatic osteoporosis is considered a relative contraindication for lung transplantation
3. DIAGNOSIS AND DEFINITIONS
jj Dual-energy X-ray absorptiometry (DXA) represents the gold standard for BMD measure-
ment in CF 
js The effective radiation dose is usually <1 mSv per measured site.
js Measurements concern the following sites: lumbar spine and femoral neck.
js T-score refers to the number of standard deviations (SD) above or below the mean 
BMD of a gender-matched young adult (25-30 years old) control population.
js Z-score refers to the number of standard deviations (SD) above or below the mean 
BMD of an age- and gender-matched control population.
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jj Definitions
js For postmenopausal women and men > 50 years, the T-score is recommended.
 – Osteoporosis is defined as a T-score lower than -2.5 SD
 – Osteopenia is defined as a T-score between -1 and -2.5 SD
js For women prior to menopause and men < 50 years, the Z-score is recommended.
 – A Z-score of -2.0 SD or lower is defined as “CF-related low BMD”. 
 – A Z-score above -2.0 SD is “within the expected range for age”. 
 – Osteoporosis cannot be diagnosed in premenopausal women and in men under the 
age of 50 on the basis of BMD alone. For this population, the term osteoporosis 
should be reserved for those with a Z-score <-2.0 SD and a significant fracture 
history (low trauma fracture of a lower limb long bone, vertebral compression fracture, 
or two or more upper limb long bone fractures). 
 – In young adult CF patients, the predictive value of BMD for the risk of fracture is not known.
4. ASSESSMENT OF BONE HEALTH IN CF
jj Annual measurement of 25-hydroxyvitamin D blood levels, ideally at the end of winter when 
levels are at their nadir. 
js 1, 25-dihydroxyvitamin D levels should NOT be used to assess vitamin D status be-
cause they may be low, high or normal in subjects with vitamin D deficiency.
jj Annual measurement of serum calcium, phosphorus, alkaline phosphatase, creatinine.
jj Annual measurement of urinary calcium excretion (24h urine collection or ratio of calcium/
creatinine in a fasting spot, morning urine sample).
jj Regular assessment for fractures.
jj Screening for bone disease in adult CF patients with DXA 
js Baseline measurements: 1) at early adulthood (after longitudinal bone growth has stop-
ped) or, if not previously done, at transition to adult CF centre and 2) at evaluation for 
listing for lung transplantation. 
js Repeat DXA measurements:
 – If possible using the same machine and methodology. Assessment of DXA timing 
should be included in the annual review (see also Chapter “Annual Evaluation”).
 – The frequency of measurements would depend on the results of previous DXA, the 
presence/evolution of risk factors and the proposed interventions. 
 – For adult CF patients DXA are recommended every 2 to 5 years depending 
on the T or Z score. 
 – Comparison of serial DXA measurements: a change of BMD (measured in g/m2) 
greater than 3% is considered to be significant.
jj Bone remodeling biomarkers
js The biomarker most commonly used in clinical practice is β-crosslaps (bone resorption 
biomarker). N-terminal propeptide of type-1 procollagen (P1NP) (bone formation bio-
marker) is used in some centers. 
js As opposed to less specific bone-related biochemical parameters such as alkaline 
phosphatase and fasting calcium/creatinine excretion, the more bone-specific remo-
deling biomarkers should NOT be routinely measured in all CF patients but rather in 
selected cases, before and on osteoporosis treatment.
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jj Indications for evaluation by a bone disease specialist 
js T-score < 2.5 SD or Z-score < 2.0 SD 
js Low trauma fracture
js Difficult to treat vitamin D deficiency despite optimal dosing and good adherence 
(see Table 3)
5. PREVENTION AND TREATMENT OF BONE DISEASE
5.1 General recommendations for the prevention and treatment of bone  
disease (Table 2)
Table 2:  General recommendations for the prevention and treatment of bone 
disease in CF (adapted from1) 
Optimal nutritional status*a
– Sufficient BMI
– Correction of vitamin D insufficiency (confirm adherence, dosing)
– Calcium supplementation in case of inadequate intake
Physical activity, weight bearing exercise
Use of corticosteroids to be minimized whenever possible
In case of sex steroid deficiency*b hormonal replacement therapy may be indicated 
Patient education on the importance of good bone status and the risks of bone disease*c 
* a See also Chapter “Nutrition”
*b Assessed by morning total (and possibly free) testosterone in males, oestradiol in non-menstruating females and 
gonadotropins in both genders
*c Bone disease is associated with decreased quality of life, pain impeding physiotherapy and risk of pulmonary exacer-
bations. Osteoporosis is a relative contraindication for lung transplantation
5.2 Vitamin D supplementation
jj Supplementation with vitamin D3 (cholecalciferol) is superior to vitamin D2 (ergocalciferol). 
jj Target blood levels of 25-hydroxyvitamin D in CF:
js Desirable > 20 ng/ml (50 nmol/l) 
js Ideal > 30 ng/ml (75 nmol/l) and < 45 ng/ml (112.5 nmol/l)
jj Serum 25-hydroxyvitamin D levels should not exceed 100 ng/ml (250 nmol/l), due to in-
creased risk of hypercalcemia.
jj Vitamin D requirements vary enormously between individual CF patients but the routine 
dose in this context is approximately 2’000 IU/day. 
jj Different vitamin D substitution regimens have been described in the literature and prac-
tices vary among different centres. A strategy that could be applied for vitamin D supple-
mentation of CF patients is shown in Figure 1.
js Strategies to improve vitamin D absorption may also be implemented, such as vitamin 
D taken with fat containing food and with pancreatic enzymes.
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Figure 1: Algorithm for vitamin D (vitD) supplementation in adult CF patients2,3
25-OH vitD < 20 ng/ml
(50 nmol/l)
1. Oral vitD 2000 IU/day OR
2. Oral vitD 14000 IU/week OR
3. Bolus supplementation: 100.000 IU orally at D0 and at D30 AND initiate
    daily supplementation with 1000-2000 IU/day orally
Recontrol vitD levels after 3 months
Still 25-OH vitD <20 ng/ml 
(50 nmol/l)
 despite good compliance
Still 25-OH vitD <20 ng/ml 
(50 nmol/l)
despite good compliance
• Desirable 25-OH vitD levels:
>20ng/ml (>50 nmol/l)
• ideal 25-OH vitD levels:
>30 ng/ml (>75 nmol/l)
Titrate oral substitution by increasing the
dose to 2000 – 6000 IU/day orally, but not
more than 10.000 IU/day











Consider referral to a bone disease
specialist
js Weekly intake regimens of vitamin D (weekly equivalent of the daily doses) can be pro-
posed to improve adherence to treatment.
js Example: if a patient takes 2000 IU/day orally → a dose of 2000 IU x 7 = 14000 IU once 
a week orally can be prescribed.
js Cave: If the serum calcium concentration is elevated, a concomitant primary hyperpa-
rathyroidism should be suspected and serum PTH checked, possibly indicating the 
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VitD3 Streuli® injectable 
solution
300.000 IU/ml Oral, IM IV administration is 
contraindicated
Zymad® 200.000 IU/ml Oral Available in France
Uvedose® 100.000 IU/ml Oral Available in France
VitD3 Streuli® 4000 IU/ml Oral Dosing pipette, 0.1 ml scale
VitD3 Wild® 500 IU/drop Oral
EveryD3® 600 IU/drop Oral
Vi-De 3® 100 IU/drop
4500 IU/ml
Oral 20 drops = 2000 IU
Table 4: Examples of combined Calcium and vitamin D3 supplementation 
Calcium (mg) Vitamin D3 (IU) Comment
Calcimagon D3®  500  400 Chewable tablets 
(can also be dissolved in 
water) 
Calcimagon D3®  500  800 Chewable tablets 
(can also be dissolved in 
water)
Calcimagon D3 Forte® 1000  800 Chewable tablets 
(can also be dissolved in 
water)
Calcium D3 Sandoz 500/1000®  500 1000 Chewable tablets 
(can also be dissolved in 
water)
need of evaluation by an endocrinologist. In this case, vitamin D substitution is still 
recommended when 25-hydroxyvitamin D level is below 50 nmol/l.
jj Tables 3 to 5 show some examples of available vitamin D supplements.
jj Supplementation of vitamin D3 in its active form 1,25 dihydroxyvitamin D (calcitriol, 
Rocaltrol® 0.25 μg 1x/day p.o.) should be reserved for patients with severe renal  insufficiency 
(ClCr <30 ml/min) or hypoparathyroidism. Co-administration of calcium carries a risk of 
hypercalcemia and for that reason close monitoring of serum calcium levels is indicated. 
(continued)
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Calcium D3 Sandoz 1000/880® 1000  880 Powder
Calcium D3 Mepha
1200/800®
1200  800 Effervescent tablets
Kalcipos-D3®  500  800 Tablets
jj Calcium supplementation may not be necessary for all patients. Obtain a dietary history 
concerning consumption of milk products and water rich in calcium.
5.4 Bisphosphonates
jj The indications for bisphosphonate use in adult CF patients are presented in Table 6. 
js In severely vitamin D deficient patients, vitamin D should always be given as 
first intervention! Marked increases in bone mineral density may be observed after 
calcium and vitamin D supplementation. In these cases, specific treatment with bisphos-
phonates or other medications should be reevaluated as it may no longer be necessary.
Table 5: Examples of combined multivitamin preparations containing vitamin D
Vitamin D3 (IU) Comment
AquADEKs tablets® 600  IU/tablet Chewable tablets. Contains vitamins A, D, E, K and 
hydrosoluble vitamins. Available in the USA, included 
in the LMIC/GGML*
AquADEKs liquid® 600 IU/mL Contains vitamins A, D, E, K and hydrosoluble 
 vitamins. Available in the USA
DEKAs Plus tablets® 2000 IU/tablet Chewable tablets. Contains vitamins A, D, E, K and 
hydrosoluble vitamins. Available in the USA
DEKAs Plus softgel® 3000 IU/softgel Contains vitamins A, D, E, K and hydrosoluble vitamins.
Available in the USA, included in the LMIC/GGML*
DEKAs Plus liquid® 750 IU/mL Contains vitamins A, D, E, K and hydrosoluble vitamins. 
Available in the USA, included in the LMIC/GGML*
DEKAs Essential 
capsules®
2000 IU/capsule Contains only vitamins A, D, E, K. Available in the USA
DEKAs Essential 
liquid®
2000 IU/mL Liquid. Contains only vitamins A, D, E, K. Available in 
the USA
Supradyn Energy® 200 IU/tablet Tablets, effervescent tablets. Contains vitamins A, D, 
E, K and hydrosoluble vitamins.
Supradyn Vital 50+® 200 IU/tablet Tablets, effervescent tablets. Contains vitamins A, D, 
E (no vitamin K) and hydrosoluble vitamins.
*GGML=Geburtsgebrechenmedikamentenliste, LMIC= Liste de médicaments en matière d’infirmités congénitales 
(See Chapters “Nutrition” and “Administrative information”)
5.3 Calcium supplementation (see also Chapter “Nutrition”)
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jj Monitoring response to treatment
js DXA after 12 months of bisphosphonate treatment. 
js β-crosslaps (bone resorption biomarker) before, and several months after introduction 
of an osteoporosis treatment and once a year thereafter. For the general population a 
decrease of β-crosslaps by 40% suggests treatment efficacy.
jj Treatment duration: 
js There are no official statements on the duration of bisphosphonates in CF patients. 
Nevertheless, there are rare major side effects of long-term bisphosphonate use (such 
as subtrochanteric or diaphyseal fractures, jaw osteonecrosis) which can also occur in 
patients with CF.
Table 6:  Indications for treatment with bisphosphonates in adult CF patients 
(adapted from1)* 
History of low trauma fracture
Lumbar spine or femoral neck or total hip Z/T score ≤ -2 SD and evidence of bone loss > 4% 
per year on serial DXA measurements, despite optimal clinical care
Solid organ transplantation awaited or done and Z/T score ≤ -1.5 SD
Continuous systemic corticosteroids > 3 months and T score ≤ -1.5 SD
*vitD deficiency should be corrected and calcium supplementation optimized before initiating bisphosphonates
Table 7: Examples of bisphosphonates and their dosing
Mode of administration Dosage
Alendronate* Oral 70 mg / week
Risedronate Oral 35 mg / week
Ibandronate Oral 150 mg / month
Ibandronate IV 3 mg /3 months
Zoledronate IV 5 mg/year
*It also exists in an oral effervescent form (Binosto®)
Cave: when an antiresorptive treatment is initiated in a patient with a bone mineralization 
defect, there is an increased risk of symptomatic hypocalcemia.
jj Examples of available bisphosphonates are presented in Table 7. 
js Oral bisphosphonates may cause erosive oesophagitis. Patient should be instructed 
to stay upright (not lie down) for at least 30 minutes and until after first food of the day.
js Bisphosphonates and renal function: 
 – Oral bisphosphonates may be given safely (after excluding and/or correcting vitamin
D deficiency) when the creatinine clearance (ClCr) is ≥ 20-30 ml/min.
 – For iv ibandronate, dosage adaptation is necessary when creatinine clearance (Cl
Creat) is between 20 and 30 ml/min (i.e. ibandronate 2 mg administered in 1 hour).
 – IV zoledronate is contraindicated when ClCr is < 35 ml/min.
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js According to the recommendations for postmenopausal osteoporosis of the American 
Association of Clinical Endocrinologists and the American Society for Bone and Mineral 
Research, bisphosphonate treatment should be evaluated after 3 years of administra-
tion and should not exceed 5 years. Benefits and potential severe side effects should be 
taken into consideration for continuing the treatment.
5.5 Other medications
jj Indication for treatment with any of these agents needs to be discussed with a bone di-
sease specialist. 
js Denosumab (Prolia®), a human monoclonal antibody, is an antiresorptive drug given 
every 6 months subcutaneously. It is approved for use in postmenopausal women with 
risk of osteoporosis and in male osteoporosis independent of the age.  Although there 
is no CF-specific contraindication for its use, for adults with CF no data are available yet. 
Cave: severe rebound effect after Denosumab discontinuation and in creased risk of 
vertebral fractures in 10% of patients. These side effects may probably be avoidable with 
potent bisphosphonates given before and after (for 1 to 2 years) denosumab. 
js Teriparatide (Forsteo®), a recombinant human parathyroid hormone, is currently the only 
approved anabolic medication that reduces the incidence of osteoporotic fractures. It is 
indicated for very severe osteoporosis, particularly for patients who have a new vertebral 
fracture while receiving an antiresoptive therapy and for corticosteroid-induced osteo-
porosis. For adults with CF no data are available yet.
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